SS&C Intralinks Wins Appreciation Award at Korea New Drug Development Awards8 April 2022
An awards ceremony recognized Biopharma firms and service providers that have fostered growth in the Biohealth industry and new drug development in South Korea.
SS&C Intralinks was honored to receive an Appreciation Award at the 23rd Korea New Drug Development Awards Ceremony held at Hotel Samjung in Seoul on February 23, 2022.
Each year, the Korea Drug Research Association awards top Biopharma firms and service providers that demonstrate exceptional innovation and strengthen global collaboration in the Biohealth industry and new drug development.
This award recognizes the impact Intralinks’ business development and licensing solutions have made on increasing transparency within the research and development and clinical demonstration process for the local Pharmaceutical and Bioindustry in South Korea.
In particular, our virtual data room (VDR) was recognized for fostering license-out and enabling Life Sciences professionals to raise capital, evaluate opportunities, expedite due diligence and maximize business development efforts.
On behalf of the SS&C Intralinks team, I would like to extend our appreciation to the Korea Drug Research Association for its recognition.
Learn more about our DealCentre™ for Life Sciences solution purpose-built for the variety and complexity of life sciences projects by clicking here.
SunSik Kim is a country director at Intralinks. Since 2015, he has managed to establish, develop and grow sales in South Korea, one of the most dynamic and innovative capital markets in the world. Prior to Intralinks, he worked for IBM as a sales director and client system manager for almost 14 years. He started his career working for South Korean firms SsangYong and CJ Group, where he was involved in business planning, strategy development and corporate restructuring.
Stay IN the know
Sign up for our newsletter for must-read market analysis and thought leadership, delivered right to your inbox.